Patents Examined by Shengjun Wang
  • Patent number: 10966978
    Abstract: The present invention relates to HDM2-p53 interaction inhibitors for use in the treatment of cancer, wherein the drug is administered by a high dose intermittent dosing regimen. The present invention relates in particular to the HDM2-p53 interaction inhibitor HDM20I and the dosing regimen di, d8 of a 4 week cycle.
    Type: Grant
    Filed: November 14, 2017
    Date of Patent: April 6, 2021
    Assignee: Novartis AG
    Inventors: Stephane Ferretti, Nelson Guerreiro, Sebastien Jeay, Astrid Jullion, Christophe Meille, Jens Wuerthner
  • Patent number: 10959993
    Abstract: The present invention is directed to a combination therapy involving a selective Bcl-2 inhibitor and a MEK inhibitor for the treatment of a patient in need of such a therapy. The patient in need of the combination therapy is suffering from cancer, such as acute myeloid leukemia.
    Type: Grant
    Filed: November 3, 2016
    Date of Patent: March 30, 2021
    Assignee: Genentech, Inc.
    Inventors: Mark Merchant, Deepak Sampath, Marina Konopleva, Lina Han
  • Patent number: 10959972
    Abstract: Provided herein are methods of treating multiple sclerosis with a fumarate, wherein the fumarate is a dialkyl fumarate, a monoalkyl fumarate, a combination of a dialkyl fumarate and a monoalkyl fumarate, a prodrug of monoalkyl fumarate, a deuterated form of any of the foregoing, or a pharmaceutically acceptable salt, clathrate, solvate, tautomer, or stereoisomer of any of the foregoing, or a combination of any of the foregoing. The methods provided herein improve the safety of treatment by informing and monitoring patients undergoing treatment regarding progressive multifocal leukoencephalopathy, and/or by monitoring lymphocyte count.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: March 30, 2021
    Assignee: BIOGEN MA INC.
    Inventors: Mark Novas, Rui (Ray) Zhang
  • Patent number: 10952984
    Abstract: The present disclosure provides an all-trans retinoic acid injectable formulation and its application for a preparation of a pharmaceutical product for treating tumor. The all-trans retinoic acid injectable formulation includes all-trans retinoic acid and solubilizers. The apparent solubility of the all-trans retinoic acid is increased from 0.01 mg/mL to 0.1 mg/mL or more. The injectable formulation can reduce the activity of an infiltrated immuno-suppressive cell population within blood or tumor tissue of a cancer patient, and improve immune clearing effects against tumors. It can be applied independently or together with other pharmaceutical products to inhibit tumor growth and prevent tumor recurrence.
    Type: Grant
    Filed: August 17, 2017
    Date of Patent: March 23, 2021
    Inventors: Yuhong Xu, Xiaolong Chen, Anjie Zheng, Lieyi Wu
  • Patent number: 10945998
    Abstract: A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.
    Type: Grant
    Filed: March 8, 2016
    Date of Patent: March 16, 2021
    Inventors: Sanford Markowitz, Stanton Gerson, Amar Desai, Won Jin Ho
  • Patent number: 10942183
    Abstract: A method that includes testing for the presence of a phosphorylated Ser294 (phospho-Ser294) progesterone receptor (PR). A method that includes determining the expression level of a gene in a patient sample and comparing it to a control sample.
    Type: Grant
    Filed: April 5, 2018
    Date of Patent: March 9, 2021
    Assignee: Regents of the University of Minnesota
    Inventors: Carol Ann Lange, Todd P. Knutson
  • Patent number: 10918639
    Abstract: The present invention relates to the combination of stimulators of soluble guanylate cyclase (sGC stimulators) with mineralocorticoid receptor antagonists (MR antagonists) and to the use of the combination for the treatment and/or prophylaxis of cardiac and cardiovascular disorders, of renal and cardiorenal disorders, of pulmonary and cardiopulmonary disorders and also for the treatment and/or prophylaxis of fibrotic disorders.
    Type: Grant
    Filed: October 5, 2017
    Date of Patent: February 16, 2021
    Inventors: Peter Kolkhof, Peter Sandner
  • Patent number: 10918609
    Abstract: Disclosed herein is a pharmaceutical composition for treating or preventing inflammatory diseases or arthritis, which includes 2-methoxy-4-(3-(4-methoxyphenyl)prop-1-en-1-yl)phenol or a pharmaceutically acceptable salt thereof as an active ingredient. The pharmaceutical composition exhibits superior therapeutic efficacy against arthritis without any side effects such as toxicity, etc.
    Type: Grant
    Filed: February 13, 2019
    Date of Patent: February 16, 2021
    Assignee: Chungbuk National University Industry-Academic Cooperation Foundation
    Inventors: Jin Tae Hong, Hee Pom Lee, Young Wan Ham, Chun Sik Kim, Heon Sang Jung, Dae Hwan Kim
  • Patent number: 10898491
    Abstract: A method of treating or preventing a bacterial infection of a subject may include combining levofloxacin and a diluent to form a treatment solution and topically administering the treatment solution to the subject to bath a skin area with the treatment solution. The treatment solution may include levofloxacin oral solution.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: January 26, 2021
    Inventor: Jay Richard Ray, II
  • Patent number: 10894087
    Abstract: Among other aspects, provided herein are multi-arm polymeric prodrug conjugates of cabazitaxel-based compounds. Methods of preparing such conjugates as well as methods of administering the conjugates are also provided. Upon administration to a patient, release of the cabazitaxel-based compound is achieved.
    Type: Grant
    Filed: December 22, 2011
    Date of Patent: January 19, 2021
    Assignee: Nektar Therapeutics
    Inventor: Antoni Kozlowski
  • Patent number: 10882851
    Abstract: This invention provides quinazoline derivatives represented by the structural formula: (I); wherein: R2 is hydrogen, NR?R?, C1-7 alkyl, arylC1-7 alkyl or C3-10 cycloalkyl; R4 is amino, C1-7 alkyl, C2-7 alkenyl, C3-10 cycloalkyl, C3-10 cycloalkenyl, aryl, heterocyclic, arylalkyl, heterocyclic-substituted C1-7 alkyl or C3-10 cycloalkyl-C1-7 alkyl; R5 is hydrogen or C1-7 alkyl, or R5 and R4 together with the nitrogen atom to which they are attached form a heterocyclic ring; Y is a single bond, C1-7 alkylene, C2-7 alkenylene or C2-7 alkynylene; R6 is halogen, heteroaryl or aryl; R? and R? are each independently hydrogen, C1-7 alkyl-carbonyl or C1-7 alkyl; provided that R4 is not phenyl substituted with morpholino when R2 is H and R5 is H, and provided that when NR4R5 is piperazinyl, said NR4R5 is either non-substituted or substituted with methyl or acetyl; a pharmaceutically acceptable addition salt, a stereoisomer, a mono- or a di-N-oxide, a solvate or a pro-drug thereof, for the treatment of viral infections.
    Type: Grant
    Filed: January 7, 2016
    Date of Patent: January 5, 2021
    Assignee: Gilead Sciences, Inc.
    Inventors: Ling-Jie Gao, Piet André Maurits Maria Herdewijn, Steven Cesar Alfons De Jonghe, William John Watkins, Lee Shun Chong
  • Patent number: 10881669
    Abstract: Disclosed are inhibitors of the plasmodial surface anion channel (PSAC) inhibitors and the use thereof in treating or preventing malaria in an animal such as a human, comprising administering an effective amount of an inhibitor or a combination of inhibitors. An example of such an inhibitor is a compound of formula I, or a pharmaceutically acceptable salt thereof, wherein R1 to R7 are as described herein.
    Type: Grant
    Filed: May 21, 2018
    Date of Patent: January 5, 2021
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Sanjay A. Desai, Ajay D. Pillai
  • Patent number: 10874673
    Abstract: Methods of inhibiting the replication of influenza viruses in a biological sample or patient, of reducing the amount of influenza viruses in a biological sample or patient, and of treating influenza in a patient, comprises administering to said biological sample or patient an effective amount of a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A compound is represented by Structural Formula (IA) or a pharmaceutically acceptable salt thereof, wherein the values of Structural Formula (IA) are as described herein. A pharmaceutical composition comprises an effective amount of such a compound or pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, adjuvant or vehicle.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: December 29, 2020
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Paul S. Charifson, Michael P. Clark, Upul K. Bandarage, Randy S. Bethiel, John J. Court, Hongbo Deng, Ioana Davies, John P. Duffy, Luc J. Farmer, Huai Gao, Wenxin Gu, Dylan H. Jacobs, Joseph M. Kennedy, Mark W. Ledeboer, Brian Ledford, Francois Maltais, Emanuele Perola, Tiansheng Wang, M. Woods Wannamaker, Randal Byrn, Yi Zhou, Chao Lin, Min Jiang, Steven Jones, Ursula A. Germann, Francesco G. Salituro, Ann Dak-Yee Kwong
  • Patent number: 10875876
    Abstract: Inhibitors of HBV replication of Formula (I-A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R1 to R8 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.
    Type: Grant
    Filed: June 28, 2016
    Date of Patent: December 29, 2020
    Inventors: Sandrine Marie Helene Vendeville, Stefaan Julien Last, Samuël Dominique Demin, Sandrine Céline Grosse, Geerwin Yvonne Paul Haché, Lili Hu, Serge Maria Aloysius Pieters, Geert Rombouts, Koen Vandyck, Wim Gaston Verschueren, Pierre Jean-Marie Bernard Raboisson
  • Patent number: 10869853
    Abstract: The instant disclosure features, among other things, compositions and methods for treating an autism spectrum disorder in a human. The compositions comprise an effective amount of: (1) an isothiocyanate (e.g., sulforaphane or a derivative thereof) or (2) a glucosinolate, and optionally, an enzyme, to thereby treat an autism spectrum disorder and/or reduce the severity of at least one symptom of the disorder. Methods for preparing such compositions are also featured.
    Type: Grant
    Filed: October 2, 2015
    Date of Patent: December 22, 2020
    Inventors: Paul Talalay, Andrew Zimmerman
  • Patent number: 10864182
    Abstract: Described herein is the use of sulindac in the treatment of fragile X syndrome (FXS).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: December 15, 2020
    Inventor: David Brown
  • Patent number: 10864197
    Abstract: Methods of treatment comprising administering a compound having structure (I), or a pharmaceutically acceptable salt thereof, or administering a pharmaceutical composition comprising the compound of structure (I) or pharmaceutically acceptable salt thereof, are provided.
    Type: Grant
    Filed: May 22, 2020
    Date of Patent: December 15, 2020
    Assignee: RETROPHIN, INC.
    Inventors: Radko Komers, Alvin Shih
  • Patent number: 10857138
    Abstract: Pharmaceutical compositions comprising aztreonam or a pharmaceutically acceptable derivative, and a compound of Formula (I) or a stereoisomer or a pharmaceutically acceptable derivative thereof are disclosed.
    Type: Grant
    Filed: April 17, 2015
    Date of Patent: December 8, 2020
    Inventors: Sachin Bhagwat, Snehal Rameshwar Palwe, Prashant Ratnakar Joshi, Hemant Narendra Khande, Kushal Umarkar, Mahesh Vithalbhai Patel
  • Patent number: 10842763
    Abstract: The disclosure provides methods of treating cancer in a subject or preventing a relapse or reducing the incidence of relapse of cancer in a subject in remission, comprising administering to the subject: (a) a therapeutically effective amount of an immunotherapeutic agent, e.g., an immune checkpoint blockade therapy, an adoptive cellular therapy, a marrow-infiltrating lymphocytes, an adenosine A2aR inhibitor, or an antibody; and (b) a compound having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification. Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: November 24, 2020
    Assignees: The Johns Hopkins University, Ústav organické chemie a biochemie AV {hacek over (C)}r, v.v.i.
    Inventors: Barbara Slusher, Jonathan Powell, Lukas Tenora, Pavel Majer, Andrei Jancarik, Robert Leone, Judson Englert
  • Patent number: 10835525
    Abstract: The present invention includes a method of reducing or inhibiting the kinase activity of C-KIT mutant tyrosine kinase activity in a cell or a subject, and the use of such compound for treating mutant C-KIT driven cell proliferative disorder(s) in a subject related to using a compound of the present invention: or pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: February 22, 2019
    Date of Patent: November 17, 2020
    Inventor: Vinay K. Jain